CLINICAL TRIALS PROFILE FOR SOLOSEC
✉ Email this page to a colleague
All Clinical Trials for solosec
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03935217 ↗ | A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis | Completed | Lupin Research Inc | Phase 3 | 2019-04-23 | This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis. |
NCT03937869 ↗ | Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV | Completed | Lupin Research Inc | Phase 4 | 2018-11-28 | A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for solosec
Condition Name
Clinical Trial Locations for solosec
Trials by Country
Clinical Trial Progress for solosec
Clinical Trial Phase
Clinical Trial Sponsors for solosec
Sponsor Name